Histone Deacetylase Inhibitors

Histone deacetylase inhibitors (HDAC inhibitors or HDI) are an emerging class of anticancer agents with demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range of malignancies.

Based on these preclinical findings, in recent years HDACIs have undergone a rapid phase of clinical development with many HDACIs entering Phase I–III clinical trials, both as single agents and in combination with other therapies.

In fact, several compounds in this class, including Suberoylanilide hydroxamic acid (SAHA), MS-27-275, BML-210, M344 and CI-994, are currently undergoing clinical trials.

At the moment we can offer you the following HDAC inhibitors from stock: Suberoylanilide Hydroxamic Acid (SAHA); MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A. All these compounds are in stock and can be delivered in 5-10 days. The minimum purity of HDAC inhibitors is 97%. H1NMR and LCMS analytical data are available upon request.

The following HDAC inhibitors can be delivered in about 3-6 weeks: Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

Special offer
We are pleased to offer you set of eight HDAC inhibitors* at the best current market price:
$450/8 inhibitors* x 10 mg
$950/8 inhibitors* x 50 mg
$1300/8 inhibitors* x 100 mg
Shipping and handling costs: $75
Delivery time: 5-10 days by courier from stock.
This special sale is for limited time only
* - Suberoylanilide Hydroxamic Acid (SAHA); Entinostat (MS-275); Tacedinaline (CI-994); BML-210; M344; Mocetinostat (MGCD0103); Belinostat (PXD101); Panobinostat (LBH-589).

See the following link where Exclusive Chemistry Ltd has related services that will benefit your projects: Online Chemical Catalog